• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

[Expert panel consensus on pathological diagnosis of breast cancer with neoadjuvant therapy, the 2020 version].

出版信息

Zhonghua Bing Li Xue Za Zhi. 2020 Apr 8;49(4):296-304. doi: 10.3760/cma.j.cn112151-20200102-00007.

DOI:10.3760/cma.j.cn112151-20200102-00007
PMID:32268664
Abstract
摘要

相似文献

1
[Expert panel consensus on pathological diagnosis of breast cancer with neoadjuvant therapy, the 2020 version].[《2020版乳腺癌新辅助治疗后病理诊断专家共识》]
Zhonghua Bing Li Xue Za Zhi. 2020 Apr 8;49(4):296-304. doi: 10.3760/cma.j.cn112151-20200102-00007.
2
Serbian consensus of neoadjuvant therapy for breast cancer: NeoPULSE.塞尔维亚乳腺癌新辅助治疗共识：NeoPULSE
J BUON. 2018 Mar-Apr;23(2):522-532.
3
Can pathologic complete response (pCR) be used as a surrogate marker of survival after neoadjuvant therapy for breast cancer?病理完全缓解（pCR）能否作为乳腺癌新辅助治疗后生存的替代标志物？
Crit Rev Oncol Hematol. 2015 Jul;95(1):88-104. doi: 10.1016/j.critrevonc.2015.02.011. Epub 2015 Mar 4.
4
[The development of neoadjuvant chemotherapy in breast cancer].[乳腺癌新辅助化疗的发展]
Gan To Kagaku Ryoho. 2012 Jun;39(6):876-81.
5
Professor Charles E. Geyer: neoadjuvant therapy is becoming standard of care for HER2+ breast cancer.查尔斯·E·盖耶教授：新辅助治疗正成为HER2阳性乳腺癌的标准治疗方案。
Chin Clin Oncol. 2016 Oct;5(5):71. doi: 10.21037/cco.2016.10.06.
6
Neoadjuvant pertuzumab in early HER2-positive breast cancer.新辅助帕妥珠单抗用于早期HER2阳性乳腺癌
Clin Adv Hematol Oncol. 2013 Dec;11(12):799-800.
7
[Analysis of Neoadjuvant Chemotherapy for HER2-Positive Breast Cancer in Our Department].[我院HER2阳性乳腺癌新辅助化疗分析]
Gan To Kagaku Ryoho. 2018 Oct;45(10):1504-1506.
8
Bevacizumab Addition in Neoadjuvant Treatment Increases the Pathological Complete Response Rates in Patients with HER-2 Negative Breast Cancer Especially Triple Negative Breast Cancer: A Meta-Analysis.新辅助治疗中添加贝伐单抗可提高HER-2阴性乳腺癌尤其是三阴性乳腺癌患者的病理完全缓解率：一项荟萃分析。
PLoS One. 2016 Aug 31;11(8):e0160148. doi: 10.1371/journal.pone.0160148. eCollection 2016.
9
De-escalated neoadjuvant therapy with nanoparticle albumin-bound paclitaxel and trastuzumab for low-risk pure HER2 breast cancer.低危 HER2 阳性乳腺癌患者接受白蛋白结合型紫杉醇和曲妥珠单抗新辅助降阶梯治疗的研究
Cancer Chemother Pharmacol. 2019 Jun;83(6):1099-1104. doi: 10.1007/s00280-019-03836-z. Epub 2019 Apr 8.
10
Neoadjuvant Therapy for Early-Stage Breast Cancer: Current Practice, Controversies, and Future Directions.早期乳腺癌的新辅助治疗：当前实践、争议及未来方向
Oncology (Williston Park). 2015 Nov;29(11):828-38.

引用本文的文献

1
Neoadjuvant ARX788 plus pyrotinib versus trastuzumab, pertuzumab, docetaxel and carboplatin for HER2-positive breast cancer: a randomised phase 2b trial.新辅助ARX788联合吡咯替尼对比曲妥珠单抗、帕妥珠单抗、多西他赛和卡铂用于HER2阳性乳腺癌：一项随机2b期试验
Nat Commun. 2025 Jul 1;16(1):6036. doi: 10.1038/s41467-025-61213-2.
2
Development and validation of a metabolic syndrome and its components to predict the efficacy of neoadjuvant chemotherapy in breast cancer: An observational, single-center, cohort study.代谢综合征及其组分用于预测乳腺癌新辅助化疗疗效的研究进展与验证：一项观察性、单中心队列研究
Medicine (Baltimore). 2025 Jan 10;104(2):e41221. doi: 10.1097/MD.0000000000041221.
3
The efficacy and safety of trastuzumab and albumin-bound paclitaxel with or without pyrotinib as neoadjuvant therapy for HER2-positive breast cancer: a prospective observational cohort study.
曲妥珠单抗和白蛋白结合型紫杉醇联合或不联合吡咯替尼作为HER2阳性乳腺癌新辅助治疗的疗效和安全性：一项前瞻性观察队列研究。
Gland Surg. 2024 May 30;13(5):654-662. doi: 10.21037/gs-24-81. Epub 2024 May 27.
4
A pilot trial of neoadjuvant pyrotinib plus trastuzumab, dalpiciclib, and letrozole for triple-positive breast cancer.吡咯替尼联合曲妥珠单抗、达尔西利及来曲唑用于新辅助治疗三阳性乳腺癌的一项探索性试验
MedComm (2020). 2024 Mar 10;5(3):e505. doi: 10.1002/mco2.505. eCollection 2024 Mar.
5
CACA Guidelines for Holistic Integrative Management of Breast Cancer.《中国抗癌协会乳腺癌整合诊疗指南》
Holist Integr Oncol. 2022;1(1):7. doi: 10.1007/s44178-022-00007-8. Epub 2022 Jul 5.
6
Human clinical trial using diagnostic ultrasound and microbubbles to enhance neoadjuvant chemotherapy in HER2- negative breast cancer.使用诊断超声和微泡增强HER2阴性乳腺癌新辅助化疗的人体临床试验。
Front Oncol. 2022 Oct 20;12:992774. doi: 10.3389/fonc.2022.992774. eCollection 2022.